Gestational Diabetes Mellitus. Diabetes Mellitus
Conditions
Interventions
Intervention 1: The control group received placebo twice (baseline and 21 days) in combination with calcium carbonate tablets 1000 milligram orally daily. Intervention 2: intervention group recieved 5
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Pregnant women diagnosed with gestational diabetes at the age of 18-40 years. Pregnant women diagnosed with gestational diabetes who had not a previous history of overt diabetes. Pregnant women diagnosed with gestational diabetes who do not receive vitamin D supplement. Pregnant women diagnosed with gestational diabetes who do not smoke or do not use any drugs Pregnant women with gestational diabetes who do not have any systemic diseases including liver disease, hypertension, hypothyroidism. Pregnant women diagnosed with gestational diabetes who do not have multiple pregnancies Pregnant women diagnosed with gestational diabetes who do not take any medication which affect glucose metabolism like steroids and insulin Pregnant women diagnosed with gestational diabetes who do not take and medication any glucose lowering drugs.
Exclusion criteria
Exclusion criteria: unwillingness of participants to continue the study Start of insulin therapy during intervention miscarriage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Plasma Glucose. Timepoint: at baseline of study- at the end of 6 weeks intervention. Method of measurement: commercial kit, enzymatic method.;??????? ???. Timepoint: at baseline of study- at the end of 6 weeks intervention. Method of measurement: immunoassay (Elisa) kit.;Insulin resistance index (HOMA-IR). Timepoint: at baseline of study- at the end of 6 weeks intervention. Method of measurement: using formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL-C. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: enzymatic method by using commercial kit.;Serum vitamin D concentration. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: Commercial kit.;Serum calcium. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: Commercial kit.;Serum phosphorus. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: Commercial kit.;Serum triglyceride. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: enzymatic method by using commercial kit.;Serum total cholesterol. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: enzymatic method by using commercial kit.;LDL-C. Timepoint: at study baseline and at the end of 6 weeks intervention. Method of measurement: enzymatic method by using commercial kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactkimia Seddighi
Bandare-abbas University of Medical Sciences
Outcome results
None listed